NCT05749016 2023-03-01
Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Barbara Ann Karmanos Cancer Institute